Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Cervical Dysplasia Clinical Trials

A listing of Cervical Dysplasia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (6) clinical trials

A clinical trial seeking patients for a research study of Aminolaevulinic acid, Placebo

This trial will study the effectiveness of photodynamic therapy with aminolaevulinic acid for the treatment of patients with HPV+ low grade cervical intraepithelial neoplasia (LSIL;CIN1).


Collection of Blood Bone Marrow Tumor or Tissue Samples From Patients With Cancer to Study Drug Resistance

Background Ongoing research in the Experimental and Molecular Therapeutics Sections, NCI, requires the availability of blood, serum, tumor, hair follicle and tissue samples from patients with cancer. Resistance is the underlying cause of treatment failure, and may present as acquired or intrinsic drug resistance. Patients with cancer frequently present with ...

Phase N/A

E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers

Background Metastatic or refractory/recurrent human papillomavirus (HPV)-16+ cancers (cervical, vulvar, vaginal, penile, anal, and oropharyngeal cancers) are incurable and poorly palliated by standard therapies. HPV-16+ cancers constitutively express the HPV-16 E7 oncoprotein, which is absent from healthy human tissues. Administration of T cell receptor (TCR) gene engineered T cells can ...


A clinical trial to evaluate treatments for patients with Cervical Intraepithelial Neoplasia, Cervical Cancer

LN-145 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI, for the treatment of patients with recurrent, metastatic, or persistent cervical carcinoma. The cell transfer therapy used in this study involves patients receiving a NMA lymphocyte depleting preparative regimen, followed ...


A Phase 2 clinical study for patients with Recurrent Glioma, Thyroid Adenoma, Colorectal Cancer, Lung Neoplasm, Uterine Corpus Cancer, Ovarian Cancer, Recurrent Thyroid Gland Carcinoma, Recurrent Breast Carcinoma, Recurrent Colon Carcinoma, Recurrent Liver Carcinoma, Pancreatic Cancer, Malignant neoplasm of kidney, Ductal Carcinoma In Situ, Recurrent Pancreatic Carcinoma, melanoma, Malignant neoplasm of prostate, bladder cancer, Advanced Malignant Solid Neoplasm, Recurrent Lymphoma, Renal Cell Carcinoma, Uterine Cancer, Endometrial Carcinoma, Malignant neoplasm of colon, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Refractory Lymphoma, Lymphoma, Breast Cancer, Cervical Cancer, Skin Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Head and Neck Carcinoma, Esophageal Carcinoma, Refractory Plasma Cell Myeloma, Recurrent Cervical Carcinoma, Multiple Myeloma, Recurrent Lung Carcinoma, Head and Neck Carcinoma, Recurrent Skin Carcinoma, Recurrent Bladder Carcinoma, Recurrent Malignant Solid Neoplasm, Rectal Cancer, Recurrent Plasma Cell Myeloma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Glioma, Recurrent Rectal Carcinoma, Cervical Intraepithelial Neoplasia, Liver and Intrahepatic Bile Duct Carcinoma, Gastric Carcinoma, Recurrent Colorectal Carcinoma, skin cancer, Refractory Malignant Solid Neoplasm

PRIMARY OBJECTIVES: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced ...


A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study

The purpose of this study is to evaluate the persistence of immune response in subjects who received the HPV-16/18 vaccine, seven to eight years after the last dose of primary vaccination in the HPV-058 study. No new subjects will be enrolled in this extension study.